• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过下调 GSK3β 活性,朊蛋白导致 Tau 外显子 10 包含。

Tau Exon 10 Inclusion by PrP through Downregulating GSK3β Activity.

机构信息

Molecular and Cellular Neurobiotechnology, Institute for Bioengineering of Catalonia (IBEC), Scientific Park of Barcelona, The Barcelona Institute for Science and Technology (BIST), 08028 Barcelona, Spain.

Department of Cell Biology, Physiology and Immunology, University of Barcelona, 08028 Barcelona, Spain.

出版信息

Int J Mol Sci. 2021 May 20;22(10):5370. doi: 10.3390/ijms22105370.

DOI:10.3390/ijms22105370
PMID:34065232
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8161268/
Abstract

Tau protein is largely responsible for tauopathies, including Alzheimer's disease (AD), where it accumulates in the brain as insoluble aggregates. Tau mRNA is regulated by alternative splicing, and inclusion or exclusion of exon 10 gives rise to the 3R and 4R isoforms respectively, whose balance is physiologically regulated. In this sense, one of the several factors that regulate alternative splicing of tau is GSK3β, whose activity is inhibited by the cellular prion protein (PrP), which has different physiological functions in neuroprotection and neuronal differentiation. Moreover, a relationship between PrP and tau expression levels has been reported during AD evolution. For this reason, in this study we aimed to analyze the role of PrP and the implication of GSK3β in the regulation of tau exon 10 alternative splicing. We used AD human samples and mouse models of PrP ablation and tau overexpression. In addition, we used primary neuronal cultures to develop functional studies. Our results revealed a paralleled association between PrP expression and tau 4R isoforms in all models analyzed. In this sense, reduction or ablation of PrP levels induces an increase in tau 3R/4R balance. More relevantly, our data points to GSK3β activity downstream from PrP in this phenomenon. Our results indicate that PrP plays a role in tau exon 10 inclusion through the inhibitory capacity of GSK3β.

摘要

tau 蛋白在很大程度上负责包括阿尔茨海默病(AD)在内的 tau 病,在 AD 中,tau 蛋白在大脑中积累为不溶性聚集体。tau mRNA 通过选择性剪接进行调节,外显子 10 的包含或排除分别产生 3R 和 4R 异构体,其平衡受生理调节。在这个意义上,调节 tau 选择性剪接的几个因素之一是 GSK3β,其活性被细胞朊病毒蛋白(PrP)抑制,PrP 在神经保护和神经元分化中有不同的生理功能。此外,在 AD 演变过程中已经报道了 PrP 和 tau 表达水平之间的关系。出于这个原因,在这项研究中,我们旨在分析 PrP 的作用以及 GSK3β 在 tau 外显子 10 选择性剪接调节中的作用。我们使用 AD 人类样本和 PrP 缺失和 tau 过表达的小鼠模型。此外,我们使用原代神经元培养物进行功能研究。我们的结果揭示了所有分析模型中 PrP 表达与 tau 4R 异构体之间的平行关联。在这个意义上,PrP 水平的降低或缺失会导致 tau 3R/4R 平衡增加。更重要的是,我们的数据表明 GSK3β 活性是 PrP 下游在这种现象中的作用。我们的结果表明,PrP 通过 GSK3β 的抑制能力在 tau 外显子 10 的包含中发挥作用。

相似文献

1
Tau Exon 10 Inclusion by PrP through Downregulating GSK3β Activity.通过下调 GSK3β 活性,朊蛋白导致 Tau 外显子 10 包含。
Int J Mol Sci. 2021 May 20;22(10):5370. doi: 10.3390/ijms22105370.
2
The alternative splicing of tau exon 10 and its regulatory proteins CLK2 and TRA2-BETA1 changes in sporadic Alzheimer's disease.tau外显子10的可变剪接及其调控蛋白CLK2和TRA2-β1在散发性阿尔茨海默病中发生变化。
J Neurochem. 2006 Feb;96(3):635-44. doi: 10.1111/j.1471-4159.2005.03552.x. Epub 2005 Dec 20.
3
Dysregulated coordination of MAPT exon 2 and exon 10 splicing underlies different tau pathologies in PSP and AD.MAPT 外显子 2 和外显子 10 剪接的失调协调是 PSP 和 AD 中不同 tau 病理学的基础。
Acta Neuropathol. 2022 Feb;143(2):225-243. doi: 10.1007/s00401-021-02392-2. Epub 2021 Dec 7.
4
Quantitative analysis of tau isoform transcripts in sporadic tauopathies.散发性tau蛋白病中tau异构体转录本的定量分析。
Brain Res Mol Brain Res. 2005 Jun 13;137(1-2):104-9. doi: 10.1016/j.molbrainres.2005.02.014. Epub 2005 Mar 29.
5
Transactive response DNA-binding protein 43 (TDP-43) regulates alternative splicing of tau exon 10: Implications for the pathogenesis of tauopathies.反式作用应答DNA结合蛋白43(TDP-43)调节tau外显子10的可变剪接:对tau蛋白病发病机制的影响。
J Biol Chem. 2017 Jun 23;292(25):10600-10612. doi: 10.1074/jbc.M117.783498. Epub 2017 May 9.
6
Tau and saitohin gene expression pattern in progressive supranuclear palsy.进行性核上性麻痹中tau蛋白和saitohin基因的表达模式
Brain Res. 2007 May 11;1145:168-76. doi: 10.1016/j.brainres.2007.01.098. Epub 2007 Feb 1.
7
Alternative splicing of exon 10 in the tau gene as a target for treatment of tauopathies.tau基因外显子10的可变剪接作为治疗tau蛋白病的靶点。
BMC Neurosci. 2008 Dec 3;9 Suppl 2(Suppl 2):S10. doi: 10.1186/1471-2202-9-S2-S10.
8
Regulation of alternative splicing of tau exon 10.tau外显子10可变剪接的调控
Neurosci Bull. 2014 Apr;30(2):367-77. doi: 10.1007/s12264-013-1411-2. Epub 2014 Mar 14.
9
Modulation of Tau Isoforms Imbalance Precludes Tau Pathology and Cognitive Decline in a Mouse Model of Tauopathy.tau 异构体失衡的调节可预防 tau 病小鼠模型中的 tau 病理学和认知衰退。
Cell Rep. 2018 Apr 17;23(3):709-715. doi: 10.1016/j.celrep.2018.03.079.
10
MicroRNA-132 loss is associated with tau exon 10 inclusion in progressive supranuclear palsy.MicroRNA-132 的缺失与进行性核上性麻痹中 tau 外显子 10 的包含有关。
Hum Mol Genet. 2011 Oct 15;20(20):4016-24. doi: 10.1093/hmg/ddr330. Epub 2011 Aug 1.

引用本文的文献

1
Systemic Neurodegeneration and Brain Aging: Multi-Omics Disintegration, Proteostatic Collapse, and Network Failure Across the CNS.全身性神经退行性变与脑老化:跨中枢神经系统的多组学解体、蛋白质稳态崩溃及网络功能障碍
Biomedicines. 2025 Aug 20;13(8):2025. doi: 10.3390/biomedicines13082025.
2
GSK3: A potential target and pending issues for treatment of Alzheimer's disease.GSK3:阿尔茨海默病治疗的潜在靶点和待解决问题。
CNS Neurosci Ther. 2024 Jul;30(7):e14818. doi: 10.1111/cns.14818.
3
Alzheimer's disease is an inherent, natural part of human brain aging: an integrated perspective.

本文引用的文献

1
Tau Protein as a New Regulator of Cellular Prion Protein Transcription.tau 蛋白作为细胞朊病毒蛋白转录的新调节剂。
Mol Neurobiol. 2020 Oct;57(10):4170-4186. doi: 10.1007/s12035-020-02025-x. Epub 2020 Jul 18.
2
The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of Alzheimer's disease in rodents.选择性 GSK3 抑制剂 SAR502250 具有神经保护活性,并可减轻阿尔茨海默病神经精神症状模型中啮齿动物的行为损伤。
Sci Rep. 2019 Dec 2;9(1):18045. doi: 10.1038/s41598-019-54557-5.
3
The GSK3β inhibitor, TDZD-8, rescues cognition in a zebrafish model of okadaic acid-induced Alzheimer's disease.
阿尔茨海默病是人类大脑自然老化的固有组成部分:综合视角。
Free Neuropathol. 2022 Jul 8;3:17. doi: 10.17879/freeneuropathology-2022-3806. eCollection 2022 Jan.
GSK3β 抑制剂 TDZD-8 可挽救岗田酸诱导的阿尔茨海默病斑马鱼模型中的认知功能障碍。
Neurochem Int. 2019 Jan;122:31-37. doi: 10.1016/j.neuint.2018.10.022. Epub 2018 Oct 28.
4
Prion protein stabilizes amyloid-β (Aβ) oligomers and enhances Aβ neurotoxicity in a model of Alzheimer's disease.朊病毒蛋白稳定淀粉样β(Aβ)寡聚物,并增强阿尔茨海默病模型中的 Aβ 神经毒性。
J Biol Chem. 2018 Aug 24;293(34):13090-13099. doi: 10.1074/jbc.RA118.003319. Epub 2018 Jun 10.
5
High-resolution temporal and regional mapping of MAPT expression and splicing in human brain development.高分辨率的人类大脑发育过程中 MAPT 表达和剪接的时空调制和区域定位图谱。
PLoS One. 2018 Apr 10;13(4):e0195771. doi: 10.1371/journal.pone.0195771. eCollection 2018.
6
Noncoding RNAs in Alzheimer's disease.阿尔茨海默病中的非编码 RNA。
Wiley Interdiscip Rev RNA. 2018 Mar;9(2). doi: 10.1002/wrna.1463. Epub 2018 Jan 12.
7
Glycogen synthase kinase-3 and its inhibitors: Potential target for various therapeutic conditions.糖原合酶激酶-3 及其抑制剂:各种治疗情况的潜在靶标。
Eur J Med Chem. 2018 Jan 20;144:843-858. doi: 10.1016/j.ejmech.2017.11.103. Epub 2017 Dec 9.
8
α-Synuclein Amyloids Hijack Prion Protein to Gain Cell Entry, Facilitate Cell-to-Cell Spreading and Block Prion Replication.α-突触核蛋白淀粉样纤维劫持朊病毒蛋白获得细胞进入,促进细胞间传播,并阻止朊病毒复制。
Sci Rep. 2017 Aug 30;7(1):10050. doi: 10.1038/s41598-017-10236-x.
9
iPS Cell Cultures from a Gerstmann-Sträussler-Scheinker Patient with the Y218N PRNP Mutation Recapitulate tau Pathology.携 Y218N PRNP 突变的格斯特曼-施特劳斯勒-谢因克患者的 iPS 细胞培养物重现了 tau 病理学。
Mol Neurobiol. 2018 Apr;55(4):3033-3048. doi: 10.1007/s12035-017-0506-6. Epub 2017 May 2.
10
Recent Progress in Alzheimer's Disease Research, Part 3: Diagnosis and Treatment.阿尔茨海默病研究的最新进展,第3部分:诊断与治疗
J Alzheimers Dis. 2017;57(3):645-665. doi: 10.3233/JAD-160907.